# Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

> **NCT00123968** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 326 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC-HIVDNA016-00-VP
- **BIOLOGICAL:** VRC-HIVADV014-00-VP
- **BIOLOGICAL:** VRC-DILUENT013-DIL-VP
- **BIOLOGICAL:** VRC-HIVADV014-00-VP placebo

## Key facts

- **NCT ID:** NCT00123968
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2021-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123968, "Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00123968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*